An observational study in Congenital Portosystemic Shunt and CPSS (Congenital Portosystemic Shunt), sponsored by Prof. Valérie Mc Lin. Enrolling by invitation at 26 sites in 16 countries. Open to participants aged 1 Day and older. Per ClinicalTrials.gov, last updated 2025-06-18.
Sponsored by Prof. Valérie Mc Lin · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Congenital Portosystemic Shunt (CPSS) is a rare condition important by the multiplicity and severity of associated complications.
CPSS is venous anomaly in which blood coming from the intestines only partially passes through the liver.
This leads to the accumulation of potentially toxic factors that cause systemic effects.
Complications vary among the individuals, and currently, it is challenging to predict which individuals will develop severe complications.
The IRCPSS registry is established with the aim of centralizing detailed clinical follow-up and biological information from participants around the world who suffer from Congenital Portosystemic Shunt (CPSS). A multidisciplinary consortium of experts is collaborating to enhance our understanding of the prevalence, natural history, individual risks, and physiopathology of the disease through the IRCPSS registry.
592 studies on the registry are indexed under Rare Diseases; 125 are open to participants now.
This study's planned enrollment of 500 is above the median of 133 across 208 observational studies indexed under Rare Diseases.
Browse Rare Diseases studies →Prof. Valérie Mc Lin is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
neonates; children; adults
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Individual with CPSS
Exclusion Criteria:
Secondary shunt without evidence of congenital shunt
Procedure: Shunt Closure
Consist in spontaneous, surgical or interventional closure of the shunt. Depending on context, surgical intervention may also be transplantation.
Numbers of patients with spontaneous shunt closure
Time frame: 3; 6; 12; 24 months
Number of patients developing one or more complications
Time frame: 5; 10; 20 years
Number of patients undergoing preemptive closure
Time frame: 6; 12; 24 months
Plan to share: Undecided — undecided
Started Apr 2018 (actual). Primary completion is estimated for Oct 2026, 102 months after the start.
Of 88 observational studies under Rare Diseases, half reached primary completion within 118 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 183. This study's planned 102 months is below that.
Rare Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Prof. Valérie Mc Lin